Comparative experience of combined medicine interferon alpha-2b + betamethasone and azelastine in the treatment of pollinosis

DOI: https://doi.org/10.29296/25877305-2022-05-15
Issue: 
5
Year: 
2022

D. Trukhan(1), Dr Med. Sci.; V. Alekseenko(2), N. Kalashnikova(2), V. Minayeva(1),
O. Shelyapina(1), K. Nesterova(1), Dr Med. Sci.; N. Bagisheva(1), Cand. Med. Sci.;
A. Mordyk(1), Dr Med. Sci., Professor; V. Goloshubina(1), Cand Med. Sci.;
M. Moiseeva(1), Cand. Med. Sci.; O. Vins(3), E. Nebesnaya(1),
1-Omsk State Medical University
2-Omsk City Polyclinic No. 12
3-Medical and Sanitary Department, Ministry of Internal Affairs of Russia, Omsk Region

Objective. To assess and compare effectiveness of the combined medicine interferon alpha-2b + betamethasone (Allergoferon® beta) and azelastine in the topical treatment of pollen allergy (pollinosis) excerbations. Materials and methods. The study design was open, prospective, randomized and comparative. This study was conducted on the basis of the Department of Allergology and Immunology of the Omsk City Polyclinic No.12. The study included 100 patients (men and women aged 18 to 55 years) who had consulted an allergist about moderate pollen allergy exacerbations. The patients were divided into two groups according to the treatment received: Group 1 (n=50) patients received azelastine for the treatment of pollinosis exacerbations; Group 2 (n=50) patients – the new combined medicine Allergoferon® beta. Patients’ conditions were assessed at baseline (Visit 1; V1) and during follow-up examinations on the day 7 (Visit 2; V2) and day 14 (Visit 3; V3). Patients’ symptoms and signs were examined, which helped to evaluate the therapy effectiveness, the presence and severity of side effects. The therapy effectiveness of pollen allergy exacerbations with these medicines was determined by analysing the frequency dynamics and clinical manifestations severity of disease exacerbations during treatment. Tolerability of the examined medicines was evaluated according to patients’ subjective assessment. Results. Control examinations of patients were conducted on the 7th and 14th days of treatment. On the 7th treatment day (V2) a positive dynamic was noted in both groups. Disappearance of nasal symptoms (rhinorrhoea – 0 points) was observed in 20% of group 1 patients and in 36% of group 2 patients (χ2=3,59; p=0,058); resolution of ocular symptoms (itchy eyelids – 0 points) – in 16 and 24% of patients in groups 1 and 2 respectively (χ2=1,33; p=0,248); absence of cough – in 20 (group 1) and 24% (group 2) of patients; absence of sneezing – in 24 (group 1) and 36% (group 2) of patients. After 14 treatment days (V3) nasal symptoms (nasal congestion – 0 points) were fully resolved in 50 and 70% of patients in groups 1 and 2 respectively (χ2=2.09; p=0.148); ocular symptoms (itchy eyelids – 0 points) resolved completely in 40 (group 1) and 64% (group 2) of patients (χ2=3.67; p=0.055); no lacrimation was observed in 56 (group 1) and 72% (group 2) of patients (χ2=1.22; p=0.268). Conclusion. Following the study results, it was noted that the use of the combined medicine interferon alpha-2b + betamethasone (Allergoferon® beta) for the treatment of patients with moderate pollen allergy exacerbations allowed us to resolve ocular and nasal disease symptoms quickly and effectively. No side effects were observed, patients noted a good tolerability of this medicine. There were no cases of treatment withdrawal or refusal.
Keywords: 
pollinosis
pollen allergy
treatment
interferon alpha-2b + betamethasone
Allergoferon® beta
azelastine

References: 
  1. Puc M. Characterisation of pollen allergens. Ann Agric Environ Med. 2003; 10 (2): 143–9.
  2. Simon D. Recent advances in clinical allergy and immunology. Int Arch Allergy Immunol. 2018; 177 (4): 324–33. DOI: 10.1159/000494931
  3. Gushchin I.S., Kurbacheva O.M. Allergiya i allergenspetsificheskaya immunoterapiya. M.: Farmarus Print Media, 2010; 228 s. (in Russ.).
  4. Khaitov R.M., Il’ina N.I. Allergologiya i immunologiya: natsional’noe rukovodstvo. M.: GEOTAR-Media, 2009; 656 s. (in Russ.)
  5. Terekhova Ye.P., Nenasheva N.M., OSIPOVA G.L. et al. Pollinosis: the choice of antihistamine drug. Effektivnaya farmakoterapiya. 2019; 15 (15): 34–45 (in Russ.). DOI: 10.33978/2307-3586-2019-15-15-34-45
  6. Federal’nye klinicheskie rekomendatsii po diagnostike i lecheniyu allergicheskogo rinita. Rossiiskaya assotsiatsiya allergologov i klinicheskikh immunologov. M., 2020 (in Russ.)
  7. Nadey E.V., Nesterova K.I. Programming currents and severity of atopic allergic airway diseases. Omskii nauchnyi vestnik. 2014; 2 (134): 41–5 (in Russ.).
  8. Khoroshilova N.V. Blokatory N1-retseptorov k gistaminu v lechenii pollinozov. Meditsinskii vestnik. 2014; 19 (668) (in Russ.). URL: lib.medvestnik.ru/articles/Blokatory-N1-receptorov-k-gistaminu-v-lechenii-pollinozov.html
  9. De Weerd N., Bhalla P.L., Sing N.B. Aeroallergens and pjllinosis: molecular and immunological characteristics of cloned pollen allergens. Acrobiologia. 2002; 18: 87–106.
  10. D’Amato G., Cecchi L., Bonini S. et al. Allergenic pollen and pollen allergy in Europe. Allergy. 2007; 62 (9): 976–90. DOI: 10.1111/j.1398-9995.2007.01393.x
  11. Allergologiya i immunologiya. Natsional’noe rukovodstvo. Pod red. Z.M. Khaitova, N.I. Il’inoi. M.: GEOTAR-Media, 2009 (in Russ.).
  12. Nadey E.V., Nechaeva G.I., Sovalkin V.I. Nekotorye aspekty epidemiologii allergicheskikh zabolevanii v usloviyakh zapadnoi Sibiri. V sb.: Budushchee – za patsientorentirovannoi kardiologiei. Mat-ly VII s»ezda kardiologov Sibirskogo federal’nogo okruga sovmestno s VII Vseross. nauchno-prakt. konf. 2017; s. 96–7 (in Russ.).
  13. Goryachkina L.A., Drobik O.S., Nasunova A.Yu. Pollinozy: sovremennyi vzglyad na problemu. Vestnik semeinoi meditsiny. 2012; 1: 10–6 (in Russ.).
  14. Goryachkina L.A., Peredkova E.V., Astaf’eva N.G. Pollinozy. V kn.: Klinicheskaya allergologiya i immunologiya. Rukovodstvo dlya praktikuyushchikh vrachei. Pod red. L.A. Goryachkinoi, K.P. Kashkina. M.: Miklosh, 2009; s. 351–62 (in Russ.).
  15. Nadey E.V., Sovalkin V.I. The role of trigger factors in formation of allergy in Omsk region. Omskii nauchnyi vestnik. 2014; 2 (134): 37–40 (in Russ.).
  16. Knyazheskaya N.P., Potapova M.O., Yakovenko I.V. Pollinoz. Atmosfera. Pul’monologiya i allergologiya. 2005; 1: 2–4 (in Russ.).
  17. Nesterova K.I., Liapin V.A., Kazakovtsev V.P. et al. Local immunity of the nasal mucosa in healthy people of a large industrial center. Rossiiskii immunologicheskii zhurnal. 2015; 9 (1): 134–7 (in Russ.).
  18. Trukhan D.I., Filimonov S.N., Bagisheva N.V. Bolezni organov dykhaniya: aktual’nye aspekty diagnostiki i lecheniya. Novokuznetsk, 2020; 227 s. (in Russ.). URL: https://www.elibrary.ru/item.asp?id=41882462
  19. Nesterova K.I., Nesterova A.A. Topicheskaya terapiya allergicheskogo rinita. V kn.: Mat-ly V Peterburgskogo foruma otorinolaringologov Rossii i IV vseross. kongr. po slukhovoi implantatsii s mezhdunar. uchast. 2016; s. 303–4 (in Russ.).
  20. Nadey E.V., Sovalkin V.I., Nesterova K.I. et al. Efficiency of combined anti-inflammatory therapy and allergenspecific immunotherapy of comorbidity allergic bronchial asthma: one-factor dispersion analysis. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2018; 24 (3): 87–95 (in Russ.).
  21. Trukhan D.I., Bagisheva N.V., Alekseenko V.A. Actual aspects of diagnosis and treatment of atopic bronchial asthma. Therapy. 2017; 8 (18): 53–62 (in Russ.).
  22. Novoe slovo v lechenii allergicheskogo rinita. XIV Mezhdunarodnyi kongress «Sovremennye problemy immunologii, allergologii i immunofarmakologii» (in Russ.).
  23. Pfaar O., Agache I., de Blay F. et al. Perspectives in allergen immunotherapy: 2019 and beyond. Allergy. 2019; 74 (Suppl 108): 3-25. DOI: 10.1111/all.14077
  24. Sotnikova N.Yu. New perspectives in the treatment of allergic rhinitis and conjunctivitis: topical medications. Infektsionnye bolezni: novosti, mneniya, obuchenie. 2017; 1: 42–50 (in Russ.).
  25. Nazarova E.V. New opportunities for the combined therapy of allergic rhinitis in real clinical practice. Rossiiskii allergologicheskii zhurnal. 2019; 1-1: 85–9 (in Russ.).
  26. Nesterova A.A., Drachuk A.I., Odarchenko I.N. et al. Allergoferon, kak preparat vybora v lechenii allergicheskogo rinita. V sb.: Nauchno-prakt. konf., posvyashch. 95-letiyu Omskoi oblastnoi klinicheskoi bol’nitsy. Sb. tr. konf. 2015; s. 356–7 (in Russ.).
  27. Strayer D.R., Carter W.A. Recombinant and natural human interferons: analysis of the incidence and clinical impact of neutralizing antibodies. J Interferon Cytokine Res. 2012; 32 (3): 95–102. DOI: 10.1089/jir.2011.0069
  28. Trukhan D., Alekseenko V., Kalashnikova N. et al. The use of combined recombinant interferon alpha-2b medications in the treatment of allergic rhinitis. Vrach. 2021; 32 (3): 73–81. (in Russ.). DOI: 10.29296/25877305-2021-03-13
  29. Ndika J., Airaksinen L., Suojalehto H. et al. Epithelial proteome profiling suggests the essential role of interferon-inducible proteins in patients with allergic rhinitis. J Allergy Clin Immunol. 2017; 140 (5): 1288–98. DOI: 10.1016/j.jaci.2017.05.040
  30. Zissler U.M., Schmidt-Weber C.B. Predicting Success of Allergen-Specific Immunotherapy. Front Immunol. 2020; 11: 1826. DOI: 10.3389/fimmu.2020.01826
  31. Scadding G.K. Other anti-inflammatory uses of intranasal corticosteroids in upper respiratory inflammatory diseases. Allergy. 2000; 55 (Suppl 62): 19–23. DOI: 10.1034/j.1398-9995.2000.055suppl62019.x
  32. Snyman J.R., Potter P.C., Groenewald M. et al.; Claricort Study Group. Effect of betamethasone-loratadine combination therapy on severe exacerbations of allergic rhinitis : a randomised, controlled trial. Clin Drug Investig. 2004; 24 (5): 265–74. DOI: 10.2165/00044011-200424050-00003
  33. Tillmann H.C., Stuck B.A., Feuring M. et al. Delayed genomic and acute nongenomic action of glucocorticosteroids in seasonal allergic rhinitis. Eur J Clin Invest. 2004; 34 (1): 67–73. DOI: 10.1111/j.1365-2362.2004.01293.x
  34. Mendoza de Morales T., Sánchez F. Clinical efficacy and safety of a combined loratadine-betamethasone oral solution in the treatment of severe pediatric perennial allergic rhinitis. World Allergy Organ J. 2009; 2 (4): 49–53. DOI: 10.1097/WOX.0b013e31819f2105
  35. Trukhan D. I., Filimonov S.N. Differentsial’nyi diagnoz osnovnykh pul’monologicheskikh simptomov i sindromov. SPb: SpetsLit, 2019; 176 s. (in Russ.). URL: https://www.elibrary.ru/item.asp?id=41392166
  36. Ryabtseva A.A., Sotnikova N.Y., Chumikov O.V. et al. Efficacy and safety of a new combined medication with recombinant interferon and betamethasone in the treatment of hay fever during periods of exacerbation. Ophthalmology in Russia. 2016; 13 (3): 197–204 (in Russ.). DOI: 10.18008/1816-5095-2016-3-197-204
  37. Gonzales-van Horn S.R., Farrar J. D. Interferon at the crossroads of allergy and viral infections. J Leukoc Biol. 2015; 98 (2): 185–94. DOI: 10.1189/jlb.3RU0315-099R
  38. Gaponyuk P.Ya. Novyi podkhod k lecheniyu bol’nykh s allergicheskim rinitom. Allergologiya i immunologiya. 2008; 9: 277 (in Russ.).